ISM5411 is designed to directly regulate the intestinal immune microenvironment so that the drug simultaneously reduces the gut inflammation seen in IBD while also promoting the repair of the ...

The company will develop a pipeline of small molecule inhibitors that target a unique lipid-binding pocket on proteins.

Researchers suggest an application to FDA may be made within the next 12 months, requesting approval to carry out a human clinical trial with the gene therapy.

A new study reveals different types of cancer have unique molecular "fingerprints" which are detectable in early stages of the disease.